The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Access to complement inhibitors for PNH treatment across Europe
In this video, Jaroslav Čermák, MD, Institute of Hematology and Blood Transfusion (ÚHKT), Prague, Czechia, briefly comments on the availability of complement inhibitors for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) across Europe. Dr Čermák shares insights from data collected across 14 countries, noting that terminal complement inhibitors are approved in all countries surveyed, while proximal complement inhibitors are approved in 12 out of 14 countries. Despite this, drug availability varies, and most patients are currently treated with C5 inhibitors, although use of proximal inhibitors is rising. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, in all countries, but I have only data from 14 countries, so not from all countries, and C5 inhibitors are approved in 12 out of these 14 countries. They are not approved in two countries, I mean, proximal complement inhibitors. Terminal complement inhibitors are approved in all countries, but in some countries, these drugs are not available at all. So, we have some data from the patients and we see that most of the patients are treated with C5 inhibitors and a smaller amount, but it’s an increasing amount of patients, is treated with proximal inhibitors...
You know, in all countries, but I have only data from 14 countries, so not from all countries, and C5 inhibitors are approved in 12 out of these 14 countries. They are not approved in two countries, I mean, proximal complement inhibitors. Terminal complement inhibitors are approved in all countries, but in some countries, these drugs are not available at all. So, we have some data from the patients and we see that most of the patients are treated with C5 inhibitors and a smaller amount, but it’s an increasing amount of patients, is treated with proximal inhibitors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
